Beta Cells

Beta Cells

Beta cells (also written β-cells) are the main hormone-producing cells in the pancreatic islets of Langerhans, making up about 50-70% of islet cell mass in healthy people. Their job is to make, store and release insulin when blood glucose rises. Glucose enters the beta cell through GLUT2 transporters and is broken down, which raises the cell’s ATP-to-ADP ratio. That closes ATP-sensitive potassium channels, changes the charge across the cell membrane, opens voltage-gated calcium channels and triggers the release of insulin-filled granules. This glucose-stimulated insulin secretion (GSIS) is how beta cells keep blood sugar stable.

Beta cell failure and loss lie at the heart of type 2 diabetes. Early on, beta cells make up for insulin resistance in the body by producing more insulin. Over time, constant exposure to high glucose (glucotoxicity), free fatty acids (lipotoxicity), inflammatory cytokines and amyloid deposits wears them out. They lose function, lose their identity and die. As insulin output falls, insulin resistance turns into high blood sugar and full diabetes.

Clinical Relevance to Retatrutide

Retatrutide may help beta cells in several ways through its three receptor targets. GLP-1 receptor activation on beta cells directly boosts glucose-stimulated insulin release, supports beta cell growth and survival in animal studies, and lowers glucagon release from alpha cells. GIP receptor activation adds a further boost to insulin release. By improving blood sugar and lowering body weight, retatrutide may also ease the glucose and fat stress that drives beta cell decline. In clinical trials, people with type 2 diabetes on retatrutide had significant drops in HbA1c, which suggests beta cell function was preserved or improved.